Medigene AG: Medigene and academic partners publish a method to enhance adoptive T-cell therapies
Article in "Cancer Research" published in collaboration with scientists from nine academic research groups in Berlin, Mu…
Article in "Cancer Research" published in collaboration with scientists from nine academic research groups in Berlin, Mu…
. - Shareholders approve all resolutions with a high majority - Dr. Keith Manchester, Ronald Scott and Dr. Gerd Zettlme…
. - T-cell receptor (TCR) T4.8-1-29 isolated from healthy blood donor - Natural high avidity and favorable preclinical…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced that researchers from Oslo University Hospital presented an up…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), today announced details on the Company's first clinical trial with T-ce…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced today that it has granted an exclusive, worldwide license for…
Medigene AG (Frankfurt, Prime Standard, MDG1) has been selected for inclusion on the TecDAX, an index of the Deutsche Bö…
Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T…
Prof. Dolores Schendel, CEO and CSO of Medigene AG (MDG1, Frankfurt, Prime Standard), will present a new approach to dev…
Prof. Dolores Schendel, CEO und CSO der Medigene AG (MDG1, Frankfurt, Prime Standard), präsentiert heute auf dem Neoanti…